Overview

Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Status:
Not yet recruiting

Trial end date:
2025-06-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of Camrelizumab in Combination With Nab-Paclitaxel and carboplatin as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Tianjin Medical University Cancer Institute and Hospital

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Carboplatin
Paclitaxel